看來載入頁面時發生了錯誤.
我們的團隊已收到通知，但若此問題持續，請透過電郵支援widget工具聯絡我們。
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM P/E Multiple | -3.2x - -3.5x | -3.3x |
| Selected Fwd P/E Multiple | -2.5x - -2.7x | -2.6x |
| Fair Value | €8.07 - €8.92 | €8.50 |
| Upside | -20.9% - -12.5% | -16.7% |
| Benchmarks | - | Full Ticker |
| BioMarin Pharmaceutical Inc. | - | NasdaqGS:BMRN |
| Ionis Pharmaceuticals, Inc. | - | NasdaqGS:IONS |
| BioCryst Pharmaceuticals, Inc. | - | NasdaqGS:BCRX |
| Intellia Therapeutics, Inc. | - | NasdaqGM:NTLA |
| Pharming Group N.V. | - | NasdaqGM:PHAR |
| KalVista Pharmaceuticals, Inc. | - | DB:4XC1 |
| - | - | - |
| Select Price / LTM EPS Ratio | ||||||||
| Benchmark Companies | ||||||||
| BMRN | IONS | BCRX | NTLA | PHAR | 4XC1 | |||
| NasdaqGS:BMRN | NasdaqGS:IONS | NasdaqGS:BCRX | NasdaqGM:NTLA | NasdaqGM:PHAR | DB:4XC1 | |||
| Historical Net Income Growth | ||||||||
| 5Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| 3Y CAGR | NM- | NM- | NM- | NM- | NM- | NM- | ||
| Latest Twelve Months | 154.6% | -23.9% | 60.8% | -7.9% | -12.3% | -62.4% | ||
| Historical Net Income Profit Margin | ||||||||
| 5 Year Average Margin | 13.5% | -37.4% | -190.2% | -746.7% | 6.5% | -564.2% | ||
| Prior Fiscal Year | 6.9% | -46.5% | -68.4% | -1326.5% | -4.3% | NA | ||
| Latest Fiscal Year | 15.0% | -64.4% | -19.7% | -896.8% | -4.0% | NA | ||
| Latest Twelve Months | 15.0% | -64.4% | -19.7% | -896.8% | -4.0% | NA | ||
| Current Trading Multiples | ||||||||
| EV / LTM EBITDA | 15.5x | -9.0x | 1192.7x | 0.4x | 150.0x | -1.9x | ||
| Price / LTM Sales | 4.0x | 6.4x | 3.4x | 12.9x | 1.8x | NA | ||
| LTM P/E Ratio | 26.6x | -9.9x | -17.4x | -1.4x | -46.1x | -3.4x | ||
| Low | Mid | High | ||||||
| Benchmark LTM P/E Ratio | -46.1x | -9.9x | 26.6x | |||||
| Historical LTM P/E Ratio | -16.0x | -4.4x | -3.2x | |||||
| Selected P/E Multiple | -3.2x | -3.3x | -3.5x | |||||
| (x) LTM Net Income | (176) | (176) | (176) | |||||
| (=) Equity Value | 558 | 587 | 617 | |||||
| (/) Shares Outstanding | 49.7 | 49.7 | 49.7 | |||||
| Implied Value Range | 11.22 | 11.81 | 12.40 | |||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | ||||
| Implied Value Range (Trading Cur) | 9.74 | 10.26 | 10.77 | 10.20 | ||||
| Upside / (Downside) | -4.5% | 0.6% | 5.6% | |||||
| Equity Value | |||||||
| Benchmark Companies | |||||||
| (in millions) | BMRN | IONS | BCRX | NTLA | PHAR | 4XC1 | |
| Value of Common Equity | 11,246 | 4,532 | 1,573 | 820 | 564 | 584 | |
| (/) Shares Outstanding | 191.8 | 159.0 | 209.0 | 103.5 | 69.2 | 49.7 | |
| Implied Stock Price | 58.65 | 28.51 | 7.53 | 7.92 | 8.15 | 11.75 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.15 | |
| Implied Stock Price (Trading Cur) | 58.65 | 28.51 | 7.53 | 7.92 | 8.15 | 10.20 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.15 | |